📰 Adams Mostafa News
Adams Mostafa News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Adams Mostafa. Real-time updates on events, politics, business and more.
May 2, 2024
X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) had its target price lifted by equities researchers at HC Wainwright from $3.00 to $5.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 352.49% from the company’s […]
May 2, 2024
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Research analysts at Brookline Capital Management lowered their Q3 2024 earnings per share (EPS) estimates for X4 Pharmaceuticals in a note issued to investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings per share of ($0.19) for […]
May 1, 2024
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Equities research analysts at Brookline Capital Management increased their FY2026 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now expects that the company will earn $0.32 per share for the year, […]
March 26, 2024
HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note released on Friday, Benzinga reports. The brokerage currently has a $3.00 price objective on the stock. Separately, B. Riley lowered X4 Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for […]
March 26, 2024
HC Wainwright reaffirmed their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research report released on Friday, Benzinga reports. They currently have a $3.00 target price on the stock. Separately, B. Riley downgraded X4 Pharmaceuticals from a buy rating to a neutral rating and reduced their target price for the […]
June 28, 2023
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CFO Adam S. Mostafa sold 5,417 shares of the firm’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $1.93, for a total transaction of $10,454.81. Following the transaction, the chief financial officer now owns 82,862 shares in […]
June 16, 2023
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CFO Adam S. Mostafa sold 5,417 shares of the firm’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $2.22, for a total transaction of $12,025.74. Following the transaction, the chief financial officer now directly owns 88,279 shares in the […]
May 10, 2023
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) – Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Friday, May 5th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.29 per share for the year, up from their […]
May 2, 2023
X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) will post its quarterly earnings results before the market opens on Thursday, May 4th. Analysts expect X4 Pharmaceuticals to post earnings of ($0.20) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link. X4 Pharmaceuticals (NASDAQ:XFOR – […]
April 29, 2023
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 3,530,000 shares, a growth of 86.8% from the March 31st total of 1,890,000 shares. Based on an average daily trading volume, of 1,340,000 shares, […]